• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Health Care Replacement Gets CBO Score

    Bryan Mc Govern
    May. 24, 2017 03:50PM PST
    Biotech Investing
    Biotech Investing

    A CBO report indicates 23 million would lose health coverage by 2026.

    The disputed health care repeal bill pushed by Republican congress members received an updated review from the nonpartisan Congressional Budget Office, three weeks after it was put to a vote.
    The CBO score revealed 23 million people would lose insurance within the next decade thanks to the American health Care Act.
    “In 2026, an estimated 51 million people under age 65 would be uninsured, compared with 28 million who would lack insurance that year under [Obamacare],” read the report.

    CBO’s big findings, in chart form, from @haeyoun and @KevinQ https://t.co/HGZFUSY29x pic.twitter.com/Hg9t7dftsp

    — Margot Sanger-Katz (@sangerkatz) May 24, 2017


    The proposed bill would cause a reduction in the federal budget by $119 billion over the next decade. “That is $32 billion less in net savings projected to be achieved under an earlier version of the bill,” per CNBC.

    Response from top GOP members

    Health Human Services Secretary Tom Price attacked the CBO score following its reveal.
    “The CBO was wrong when they analyzed Obamacare’s effect on cost and coverage, and they are wrong again,” Price said in a statement.
    On the other hand, House Speaker Paul Ryan seemed content with the results.
    “This CBO report again confirms that the American Health Care Act achieves our mission: lowering premiums and lowering the deficit,” the speaker said in a statement following the announcement.
    A CBO score is used as a template for the reach and impact of any proposed bill from the US Congress. Back in [date] members of the house re-introduced a new version of the Obamacare-repeal and forced a vote on the floor despite not having a revised score.
    Earlier in May, the vote on the bill narrowly moved it up to the Senate, where it’s expected to undergo substantial changes to its most problematic elements. It was revealed some congress members voted on the bill despite not reading it entirely.
    The decision to push through this legislation without an official score appeared odd and inappropriate to Democratic members of congress.

    Investor Takeaway

    Despite the presidency, control of both Senate and Congress, Republicans can’t seem to put together a viable bill to complete a repeal promise on Obamacare. It seems likely the path to tax reform will also be rocky and many analysts have already expressed doubt in the capability of this administration to pass this crucial amendment.
    The CBO score also reveals how rushed the bill was and how much work GOP senators have ahead to get a bill that would prevent these heavy losses in insurance.
    Don’t forget to follow @INN_LifeScience for real-time updates!
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    health care
    The Conversation (0)

    Go Deeper

    AI Powered
    F5 Reports Strong Fourth Quarter Results with 8% Revenue Growth; FY25 Revenue of $3.1 Billion Reflects 10% Annual Growth, Driven by Transformative Industry Trends

    F5 Reports Strong Fourth Quarter Results with 8% Revenue Growth; FY25 Revenue of $3.1 Billion Reflects 10% Annual Growth, Driven by Transformative Industry Trends

    Various blister packs with pills and capsules in different colors and shapes.

    Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

    Latest News

    Nextech3D.ai Reports Milestone YTD Revenue Growth for AI Matchmaking in 2025 with a 95% Gross Margin

    Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES